3301. NovoNorm-H-C-PSUSA-00002618-201412 3302. Tandemact-H-C-PSUSA-00002417-201507 3303. Adjupanrix-H-C-1206-PSUV-0032 (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) 3304. Zoledronic acid medac-H-C-PSUSA-00003149-201408 3305. Alli (previously Orlistat GSK)-SUSA-00002220-201502 3306. Fareston-H-C-91-2999 3307. Votubia-H-C-2311-PSUV-0022 3308. Xoterna Breezhaler-H-C-003755-PSUV-0005: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 3309. Evotaz-H-C-PSUSA-10404-201607 3310. Rivastigmine Hexal-H-C-PSUSA-00002654-201501: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 3311. Ketek-H-C-354-PSUV-0060 3312. Aerinaze-H-C-PSUSA-963-201607 3313. Xiapex-H-C-PSUSA-0871-201402 3314. Xenical-H-C-PSUSA-00002220-201502 3315. Jardiance-H-C-PSUSA-00010388-201510 3316. Dacogen-H-C-2221-PSUV-0008 3317. Xalkori-H-C-PSUSA-00010042-201502: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 3318. Xolair-H-C-PSUSA-00002214-201512 3319. Xagrid-H-C-PSUSA-00000208-201609 3320. Osseor Article-20 procedure: CHMP scientific conclusions and PRAC assessment report 3321. Imvanex-H-C-2596-PSUV-0007 3322. Edarbi-H-C-2293-PSUV-08 3323. Neoclarityn-H-C-PSUSA-962-201607 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 3324. Eklira Genuair-H-C-2211-PSUSA-9005-201407 3325. Zometa-H-C-PSUSA-00003149/-01508 3326. Krystexxa-PSUSA-00010046-201501 3327. Nevanac-H-C-818-PSUV-0029 3328. Instanyl-H-C-PSUSA-00001369-201404 3329. Avastin-H-C-582-II-0059 3330. Prolia-H-C-PSUSA-00000954-201409